Sarepta Therapeutics (SRPT) Misses Q4 EPS by 29c, Sales Beat
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/24/2026
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Alphabet added to Dow Jones Industrial Average, Verizon dropped
- Chip stocks plunge, but bargain-hunters limit scale of tech rout
- FedEx falls 4% as CY2026 profit forecast misses expectations despite Q4 beat
- Oil prices finish 1% lower as investors focus on Hormuz flows after peace talks
- Needham Starts NeoVolta (NEOV) at Buy
- NextEra to discuss paying about $76 per share for Dominion, Bloomberg News reports
- Wall Street ends lower on semiconductor selloff as AI spending concerns mount
- Campbell Soup (CPB) Declares $0.39 Quarterly Dividend; 7.7% Yield
- KKR launches Helix with over $10 billion to build AI infrastructure
Sarepta Therapeutics (SRPT) PT Lowered to $91 at RBC Capital
March 1, 2017 6:35 AM ESTRBC Capital lowered its price target on Sarepta Therapeutics (NASDAQ: SRPT) to $91.00 (from $98.00) while maintaining a Outperform rating amid conservative guidance.
Analyst Simos Simeonidis commented, "Sarepta provided sales guidance for EXONDYS 51 on tonight's call, which clearly disappointed investors (SRPT... More
